Given the compelling genetic and biochemical evidence that has implicated amyloid-β (Aβ)
in the pathogenesis of Alzheimer's disease, many studies have focused on ways to inhibit …

Many new therapeutics for Alzheimer's disease delay the accumulation of amyloid-β (Aβ) in
transgenic mice, but evidence for clearance of preexisting plaques is often lacking. Here, we …

Alzheimer's disease (AD) is a progressive, degenerative disorder of the brain and the most
common form of dementia among the elderly. As the population grows and lifespan is …

Antibodies against Aβ have been suggested as potential therapeutic strategies for the
treatment of Alzheimer disease (AD) for nearly 8 years. Animal studies have been very …

The amyloid cascade hypothesis states that overproduction of amyloid-beta peptide
(Aβ/AβP) or failure to clear this peptide, leads to Alzheimer's disease (AD) primarily through …

The success of active and passive anti-Aβ immunotherapies in both preventing and clearing
parenchymal amyloid in transgenic mouse models, led to the initiation of an active anti-Aβ …

Amyloid-β (Aβ) is a normally soluble 39–43 amino peptide. Genetic and biochemical data
strongly suggest that the conversion of Aβ from soluble to insoluble forms with high β-sheet …

Alzheimer's disease is a major health problem with limited available medical treatment
options. Immunotherapy is one approach with the potential to slow or reverse the disease …

Alzheimer's disease (AD) represents the third leading cause of death in the US and the
leading cause of dementia in the elderly population. Until recently, there was little hope of …

There is substantial and compelling evidence that aggregation and accumulation of amyloid
β protein (Aβ) plays a pivotal role in the development of Alzheimer's disease (AD); thus …